Business Description
QuidelOrtho Corp
NAICS : 339112
SIC : 5047
ISIN : US2197981051
Total Employee Number:
6,500Description
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.55 | |||||
Debt-to-EBITDA | -5.31 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.1 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | -47.8 | |||||
3-Year Book Growth Rate | -27.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.43 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.17 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 0.8 | |||||
Cash Ratio | 0.15 | |||||
Days Inventory | 146.99 | |||||
Days Sales Outstanding | 47.37 | |||||
Days Payable | 59.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -9.76 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.96 | |||||
Operating Margin % | -0.8 | |||||
Net Margin % | -45.57 | |||||
EBITDA Margin % | -20.39 | |||||
FCF Margin % | -6.12 | |||||
OCF Margin % | 0.14 | |||||
ROE % | -52.2 | |||||
ROA % | -20.24 | |||||
ROIC % | -0.4 | |||||
3-Year ROIIC % | 23.17 | |||||
ROC (Joel Greenblatt) % | -51.26 | |||||
ROCE % | -19.77 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 17.61 | |||||
PE Ratio without NRI | 12.96 | |||||
Shiller PE Ratio | 15.65 | |||||
PS Ratio | 0.44 | |||||
PB Ratio | 0.64 | |||||
Price-to-Operating-Cash-Flow | 186.77 | |||||
EV-to-EBIT | -3.96 | |||||
EV-to-Forward-EBIT | 10.37 | |||||
EV-to-EBITDA | -7.23 | |||||
EV-to-Forward-EBITDA | 6.99 | |||||
EV-to-Revenue | 1.47 | |||||
EV-to-Forward-Revenue | 1.65 | |||||
EV-to-FCF | -24.58 | |||||
Price-to-GF-Value | 0.47 | |||||
Price-to-Projected-FCF | 0.3 | |||||
Price-to-Median-PS-Value | 0.14 | |||||
Earnings Yield (Greenblatt) % | -25.25 | |||||
FCF Yield % | -13.46 | |||||
Forward Rate of Return (Yacktman) % | 69.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
QuidelOrtho Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 48,699.821 | ||
| EPS (TTM) (MXN) | -329.596 | ||
| Beta | -0.1543 | ||
| 3-Year Sharpe Ratio | -1.08 | ||
| 3-Year Sortino Ratio | -1.05 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 570.28 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 570.28 - 570.28 | ||
| Shares Outstanding (Mil) | 68.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
QuidelOrtho Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
QuidelOrtho Corp Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 17:00 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 17 days | ||
| General meeting for 2026 | 2026-06-16 08:30 | 570.28 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:10 | 570.28 (+0.00%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 12:20 | 570.28 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 17:00 | 570.28 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 570.28 (+0.00%) | ||
| 47th Annual Raymond James Institutional Investor Conference | 2026-03-03 13:40 | 570.28 (+0.00%) |
Show
Entries
QuidelOrtho Corp Frequently Asked Questions
What is QuidelOrtho Corp(MEX:QDEL1)'s stock price today?
The current price of MEX:QDEL1 is MXN570.28. The 52 week high of MEX:QDEL1 is MXN570.28 and 52 week low is MXN570.28.
When is next earnings date of QuidelOrtho Corp(MEX:QDEL1)?
The next earnings date of QuidelOrtho Corp(MEX:QDEL1) is 2026-08-05 Est..
Does QuidelOrtho Corp(MEX:QDEL1) pay dividends? If so, how much?
QuidelOrtho Corp(MEX:QDEL1) does not pay dividend.
Press Release
Articles on QuidelOrtho Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers